Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. MU
6. META
7. ACN
8. FDX
9. NVDA
10. BLZE

Go back to Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

Interpace Diagnostics (IDXG) Reports In-Line Q3 EPS

November 13, 2019 4:46 PM EST

Interpace Diagnostics (NASDAQ: IDXG) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $10.46 million.

GUIDANCE:

Interpace Diagnostics sees FY2019 revenue of $28-32 million, versus the consensus of $34... More